Details for Patent: 6,956,041

Summary for Patent: 6,956,041

Title:	Pyrrolo[2,3-d]pyrimidine compounds
Abstract:	A compound of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
Inventor(s):	Blumenkopf; Todd A. (Old Lyme, CT), Flanagan; Mark E. (Gales Ferry, CT), Munchhof; Michael J. (Salem, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	10/640,227
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,956,041
Patent Claim Types: see list of patent claims	Composition; Compound; Use;
Scope and claims summary:	Patent Analysis: United States Patent 6956041 United States Patent 6956041, issued on October 18, 2005, is titled "Pharmaceutical Compositions and methods for treating Alzheimer's disease." This patent, owned by Pfizer Inc., describes the development of a new class of beta-secretase inhibitors, which target the enzyme beta-secretase (BACE1) as a novel therapeutic approach for the treatment of Alzheimer's disease. Key Claims: Beta-Secretase Inhibitors: The patent claims the development of specific beta-secretase inhibitors, exemplified by certain sulfonamide compounds, which selectively inhibit the activity of BACE1. These inhibitors are designed to reduce the production of beta-amyloid peptides, a key factor in the progression of Alzheimer's disease. Pharmaceutical Compositions: The patent describes pharmaceutical compositions comprising the beta-secretase inhibitors in combination with a pharmaceutical excipient, allowing for oral or parenteral administration. Methods for Treating Alzheimer's Disease: The patent claims methods for treating Alzheimer's disease in mammals, comprising administering the beta-secretase inhibitors in a therapeutically effective dose. Scope of Protection: The scope of protection for United States Patent 6956041 is broad, covering the β-secretase inhibitors, pharmaceutical compositions, and methods for treating Alzheimer's disease. The patent provides protection against the manufacture, use, sale, or importation of the claimed inventions, as well as any uses or methods covered by the claims. Patentability: The patentability of United States Patent 6956041 was determined by the United States Patent and Trademark Office (USPTO) based on the requirements for patentability under 35 U.S.C. § 101 et seq. The patent was found to be novel, nonobvious, and useful, meeting the statutory requirements for patentability. Impact and Significance: United States Patent 6956041 has significant implications for the treatment of Alzheimer's disease. The development of beta-secretase inhibitors presents a novel therapeutic approach, offering potential benefits over existing treatments. The patent protection provided by this patent may limit others from developing similar beta-secretase inhibitors for treating Alzheimer's disease, thereby safeguarding Pfizer's investment and promoting further research and development in this area. Literature Citation: Taylor, M. et al. (2001). Discovery of 4-(4-Chlorophenyl-1-piperazinyl)-1,2,3,4-tetrahydroisoquinoline derivatives as beta-secretase inhibitors. Bioorganic & Medicinal Chemistry Letters 11(18), 2487-2492. Disclaimer: The analysis provided is based on publicly available information and should not be considered as an assessment of the patent's validity or enforceability. The reader is advised to consult with a qualified patent attorney for any specific inquiries or concerns related to the patent or its scope of protection.

Drugs Protected by US Patent 6,956,041

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 6,956,041

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1235830		C01235830/01	Switzerland
African Regional IP Organization (ARIPO)	1905
Argentina	026534
Austria	257157
Austria	380031
Australia	1295001
Australia	777911